Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-alpha 2b: relation to response and HBV genotype


Creative Commons License

Sonneveld M. J. , Rijckborst V., Cakaloglu Y., Simon K., Heathcote E. J. , Tabak F. , ...Daha Fazla

ANTIVIRAL THERAPY, cilt.17, ss.9-17, 2012 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 17 Konu: 1
  • Basım Tarihi: 2012
  • Doi Numarası: 10.3851/imp1887
  • Dergi Adı: ANTIVIRAL THERAPY
  • Sayfa Sayıları: ss.9-17

Özet

Background: On-treatment decline of serum hepatitis B surface antigen (HBsAg) may reflect the immunomodulatory effect of pegylated interferon (PEG-IFN) for hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB). We compared HBsAg decline across HBV genotypes between combined responders (HBeAg loss and HBV DNA < 10,000 copies/ml at week 78), HBeAg responders (HBeAg loss with HBV DNA > 10,000 copies/ml) and non-responders.